Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial
Breast Cancer Research, 05/03/2012FernandezCuesta L et al. –
p53 truncating mutations were uncommon but associated with poor prognosis. No significant predictive role for p53 status was detected.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.